the fy22 defense appropriations act is anticipated to provide funding for the pcrp to support innovative, high-impact prostate cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 pcrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy22 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy22 pcrp overarching challenges:

• ·        improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

o   the mental and emotional health of patients and their families/caregivers

o   impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   translation of factors or interventions that improve quality of life outcomes and overall health and wellness

• ·        develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• ·        advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• ·        define the biology of prostate cancer progression to lethal prostate cancer to reduce death

applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

early investigator research award – letter of intent due by july 7, 2022

by march 31, 2023, postdoctoral principal investigators (pis):

• ·      must possess a doctoral degree (or equivalent)
• ·      have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)
• ·      supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
• ·      pis must have a designated mentor who is an experienced prostate cancer researcher.
• ·      must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.
• ·      must address at least one of the fy22 pcrp overarching challenges.
  • ·     the maximum allowable funding for the entire period of performance is $300,000 for direct costs.
  • ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • ·     the maximum period of performance is 2 years.

physician research award – letter of intent due by july 7, 2022

at the time of application submission, the pi must be either:

• ·    in the last year of an accredited medical residency or medical fellowship program

or

within 5 years of having initiated a faculty appointment (including instructor positions)

• ·     supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
• ·     pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
• ·     pis must have a designated mentor with an established research program in prostate cancer.
• ·     applications are strongly encouraged to demonstrate protection of at least 40% of the pi’s time for prostate cancer research (not required to be exclusive to this award). 
• ·     must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.
• ·     must address at least one of the fy22 pcrp overarching challenges.
• ·     the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 4 years.

idea development award – letter of intent due by july 7, 2022

established investigators:  independent investigators at all levels

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• ·      have the freedom to pursue individual aims without formal mentorship
• ·      have not previously received a pcrp health disparity research award and/or idea development award
• ·      have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave)
  • ·      supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the fy22 pcrp overarching challenges.
  • ·      emphasis is equally placed on innovation and impact.
  • ·      preliminary data are encouraged, but not required.
  • ·      clinical trials are not allowed.
  • ·      multidisciplinary projects are encouraged, and multi-institutional projects are allowed.
  • ·      must address at least one of the fy22 pcrp overarching challenges.
  • ·     the maximum allowable funding for the entire period of performance is $900,000 for direct costs.
  • ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • ·     the maximum period of performance is 3 years.
     
     
    for more information, please contact jill sherman, international research facilitator at  intl.research@lakeheadu.ca.

the fy22 defense appropriations act is anticipated to provide funding for the pcrp to support innovative, high-impact prostate cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 pcrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website.

the mission of the fy22 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy22 pcrp overarching challenges:

• ·        improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

o   the mental and emotional health of patients and their families/caregivers

o   impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   translation of factors or interventions that improve quality of life outcomes and overall health and wellness

• ·        develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• ·        advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• ·        define the biology of prostate cancer progression to lethal prostate cancer to reduce death

applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

funding opportunities-fy22 pcrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

exploration – hypothesis development award new for fy22 –letter of intent dye june 2, 2022

investigators at or above the level of postdoctoral fellow (or equivalent)

• ·     supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more fy22 pcrp overarching challenges.
• ·     provides investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation.
• ·     presentation of preliminary data is strongly discouraged.
• ·     reviewers will be blinded to the identity of the principal investigator (pi), collaborators, and their organization(s).
• ·     clinical research and clinical trials are not allowed.
• ·     must address at least one of the fy22 pcrp overarching challenges.
• ·     the maximum allowable funding for the entire period of performance is $100,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years.

for more information, please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca.

background and description of opportunity

the canadian glycomics network (glyconet) is a network of centres of excellence that focuses on the role of glycans (carbohydrates) in health. areas of focus for glyconet in cycle ii (2020–2024) are infectious diseases, chronic diseases (including diabetes & obesity), neurodegenerative diseases, and cancer. additional information about network research can be found at www.glyconet.ca.

a key goal of glyconet is to support research projects that are multi-disciplinary, as defined by the nce program. accordingly, this request for proposals seeks to fund projects that involve two or more research groups in different disciplines.

requirements project applications must:

• primarily address the glyconet research themes and be targeted to the role/use of glycans in reducing the economic burden and/or treatment of infectious diseases, chronic diseases, neurodegenerative diseases, and/or cancer. research in other areas of glycomics will be considered, especially those in one health.

• must have multi-disciplinary teams involving researchers as described above.

• provide a plan of how equity, diversity and inclusion will be implemented within the project team and its activities.

• lead to tangible deliverables by the end of the project, leading to translational research as the next step.

• present a knowledge mobilization plan to communicate results to partners and stakeholders.

• demonstrate a 1:1 financial match with partner funding; at least 50% of the matching funds should be cash. partner funding must be nce eligible; in particular, other canadian federal funding (e.g., cihr, nserc, sshrc, cfi) is ineligible for matching.

• projects with a higher level of matching funds (e.g. 2:1, partners:glyconet) will be viewed more favorably.

• provide information on the number and type (i.e. undergraduate, graduate student, pdf, etc.) of expected highly qualified personnel trained each year of the project.

• list the desired type of professional development training that glyconet could provide to hqp, for example, lab rotations, communication and writing skills improvement, etc.

the objectives of the program are to address systemic racism and discrimination and advance health equity for racialized and marginalized populations in canada's health systems, resulting in:

• individuals living in canada having access to appropriate, effective, and culturally sensitive health services; and,
• improved health of racialized and marginalized populations.

idrc and the united kingdom’s foreign, commonwealth and development office are pleased to announce a call for concept notes under the climate adaptation and resilience (clare) initiative.  

this call for concept notes seeks to identify transdisciplinary teams motivated to conduct action-oriented research related to one or more of clare’s three research themes:  

• understanding climate risk: research to improve our understanding of the risks associated with climate and natural hazards, by addressing gaps in the underpinning science.   
• risk-informed early action: research to improve risk-informed anticipatory action to reduce humanitarian and extreme impacts of weather, climate variability and the compounding and cascading interaction of natural hazards.  
• developing in a changing climate: research to inform development in a changing climate; action that builds resilience in the present climate and adapts to future climate.  

overview

canada’s international development research centre (idrc) and the canadian institutes of health research’s institute of population and public health (cihr-ipph) are pleased to announce a new funding opportunity to identify and implement effective knowledge mobilization strategies to integrate the canadian coalition for global health research’s (ccghr) principles for global health research (known hereafter as the principles) across the global health research ecosystem.

the principles were developed by the ccghr (now, the canadian association for global health) through a consultative process that involved over 300 people within and outside canada. developed for all those involved in global health research (ghr) — including people designing, conducting, using, teaching, learning about, assessing, funding or collaborating on ghr — the principles identify equity as a central pillar. the six principles are: authentic partnering, inclusion, shared benefits, commitment to the future, responsiveness to the causes of inequities and humility.

since their publication in 2015, the principles are increasingly seen as an exemplar in global health and health equity more broadly. however, awareness of these principles and their uptake can be further strengthened. the goal of this funding opportunity is to support the fulsome integration of the principles into action across the canadian ghr ecosystem. by supporting action on the principles, we can ensure global health is practised in an equitable way and is actively anti-colonial in its orientation.

background

for many people, the raison d’être of global health is the achievement of health equity for all people worldwide. reaffirming this view is the united nations’ sustainable development goal (sdg) #3 which seeks to “ensure healthy lives and promote well-being for all at all ages.” yet, after decades of programming and billions of dollars invested in global health, alarming health inequities persist across and within countries. the current covid-19 pandemic has further exacerbated these health inequities, underscoring the need for the field of global health to do more and to do better.

global health is an area for study, research and practice that places a priority on improving health and achieving equity in health for all people worldwide. ghr — research focused on achieving health equity globally — can make important contributions to advancing the sustainable development goals. ghr is paradoxically also culpable in perpetuating the same health inequities that it generally seeks to understand and address. for example, the rising calls for the decolonization of global health have called out practices such as ‘parasitic research’ and ‘foreign gaze’ as symptoms of the deeply entrenched power imbalances between global health researchers and populations in high-income countries (hics) and those in low- and middle-income countries (lmics).

responding to the need to ensure ghr is conducted in an ethical way, the ccghr (now, the canadian association for global health) developed the principles for global health research (the principles) through a consultative process that involved over 300 people. developed for all those involved in ghr — including people designing, conducting, using, teaching, learning about, assessing, funding or collaborating on ghr — the principles identify equity as a central pillar. the six principles are: authentic partnering, inclusion, shared benefits, commitment to the future, responsiveness to the causes of inequities and humility.

since their publication in 2015, the principles are increasingly being used by the ghr community, including by universities, non-academic research organizations, governmental bodies and non-governmental organizations, to inform training, curriculum development, research design and research funding. they are seen as an exemplar in global health and health equity more broadly. the time is ripe to mobilize their integration across the ghr ecosystem.

aim and objectives

the overall goal of this call is to support the identification and implementation of effective knowledge mobilization strategies for integrating the principles into action across the canadian ghr ecosystem. by supporting action on the principles, we hope to ensure global health is practised in an equitable way and is actively anti-colonial in its orientation.

specifically, the call seeks to support research and knowledge mobilization activities that will rigorously:

1. take stock of awareness and application of the principles within the canadian ghr ecosystem (including researchers, universities and academic settings, research and policy partners in lmics, ngos and research funders);
2. identify and implement the best strategies and opportunities for encouraging the uptake and institutionalization of the principles across the canadian ghr ecosystem; and
3. create open-access tools and resources and provide guidance and support to facilitate and scale-up the use and institutionalization of the principles in canada and around the world.

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the r&d partnership fund - electric vehicle (ev) – stream 2 program supports projects related to the development and demonstration of technologies in electric vehicles (ev) and battery manufacturing technologies in the following priority areas:

• mass light vehicles, such as cars, trucks and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• charging infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles

examples of ev and battery-focused technologies, and other ev related technologies:

• light weighting
• electrified powertrains, electric motors, transmission systems, battery management systems
• ev batteries, battery materials and chemistry, component manufacturing processes
• charging systems and ev fleet management technologies
• hydrogen and alternative fuel cell evs
• electric micro-mobility

the r&d partnership fund - c/av and smart mobility – stream 2 program supports projects related to the development, testing, validation, and demonstration of connected and autonomous vehicle (c/av) and smart mobility technologies in the following priority areas:

• mass light vehicles, such as cars, trucks, and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• transportation infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles

ovin’s r&d partnership fund - wintertech development program supports ontario small and medium enterprises (smes) and their partners to validate, test, prototype, and demonstrate new products and technologies designed to meet the unique demands of winter weather conditions.

wintertech development leverages the strengths and innovative capabilities of ontario smes in the automotive and mobility sector and our unique winter weather conditions to establish the province as a test bed for mobility products and services in severe winter weather conditions.

because of ovin's wintertech development program, ontario is a global leader in the commercialization of new winter-ready mobility technologies and solutions.

wintertech development supports projects related to technology/product/service validation, testing, demonstration and prototyping of mobility products and services in severe winter weather conditions in the following priority areas:

• mass light vehicles, such as cars, trucks, and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• transportation infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles

the fy22 tscrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy22 tscrp exploration – hypothesis development award or idea development award must address one or more of the following focus areas:

• understanding and treating the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact, including pharmacological and behavioral interventions
• strategies for eradicating tumors or other pathogenic lesions associated with tsc and tsc-associated lymphangioleiomyomatosis (lam), including gaining a deeper mechanistic understanding of tsc signaling pathways and tumor microenvironment
• preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with tsc-related seizures

applications submitted to the fy22 tscrp clinical translational research award must address one or more of the following focus areas:

• understanding and treating the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact, including pharmacological, behavioral, and surgical interventions
• strategies for eradicating tumors or other pathogenic lesions associated with tsc and tsc-associated lymphangioleiomyomatosis (lam, including gaining a deeper mechanistic understanding of tsc signaling pathways and tumor microenvironment
• preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with tsc-related seizures

funding opportunities- fy21 tscrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

exploration – hypothesis development award – letter of intent due june 30, 2022

investigators at all academic levels (or equivalent), including postdoctoral fellows

supports the initial exploration of innovative, high-risk, high[1]gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (tsc) research field.

• projects involving human subjects or human biological substances must be exempt under title 32 of the code of regulations, part 219.104(d) (32 cfr 219.104(d)) or eligible for expedited review under 21 cfr 56.110.

• preliminary data not required.

• clinical trials not allowed.

the maximum period of performance is 2 years.

• the maximum allowable funding for the entire period of performance is $150,000 in direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

idea development award – letter of intent june 30, 2022

established investigators: independent investigators at or above the level of assistant professor (or equivalent) or new-to-the-field investigator: independent investigators at or below the level of assistant professor (or equivalent) or established investigators in an area other than tsc at or above the level of assistant professor seeking to transition to a career in tsc

promotes ideas that have the potential to yield high-impact findings and new avenues of investigation.

• preliminary data expected.

• clinical trials not allowed.

• new-to-the-field investigator option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in the field of tsc research.

• applications from new-to-the-field investigators and established investigators will compete separately.

the maximum period of performance is 3 years.

• the maximum allowable funding for the entire period of performance is $500,000 in direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical translational research award – letter of intent due june 30, 2022

independent investigators at or above the level of assistant professor (or equivalent)

supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of tsc.

• applications may include correlative studies that are associated with a completed clinical trial.

• supports studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/ pharmacodynamics.

• applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.

• preclinical studies may be appropriate but must include a clinical component.

• projects that are exploratory and/or strictly animal research will not be considered for funding.

• collaborations between clinicians and research scientists are strongly encouraged.

• preliminary data required.

• the maximum period of performance is 3 years.

• the maximum allowable funding for the entire period of performance is $1,000,000 in direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tscrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.